FDA’s Project Optimus aims to transform early cancer researchNovember 14, 2023PharmacyALLAMLCMLDLBCLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Complementary medicine use common among patients on TKIsApril 24, 2019CMLLeukemia, Myelodysplasia, Transplantation
FDA clears test to monitor residual disease in CMLFebruary 22, 2019CMLLeukemia, Myelodysplasia, Transplantation
Early switch to dasatinib offers clinical benefit to CML patientsDecember 10, 2018Leukemia, Myelodysplasia, TransplantationCML
Dasatinib re-challenge feasible as 2nd attempt at TKI discontinuationDecember 7, 2018Leukemia, Myelodysplasia, TransplantationCML
Health Canada approves two tests for CML patientsNovember 15, 2018Leukemia, Myelodysplasia, TransplantationCML
FDA issues draft guidance on MRDOctober 16, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLCMLNon-Hodgkin Lymphoma
AMP publishes report on DNA variants in CMNsAugust 23, 2018CythemiasAnemiaLeukemia, Myelodysplasia, TransplantationMyelodysplastic SyndromeCML
Familial risk of myeloid malignanciesAugust 13, 2018CythemiasAnemiaLeukemia, Myelodysplasia, TransplantationAMLMyelodysplastic SyndromeCML
Global burden of hematologic malignanciesJuly 29, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
Diabetics have higher risk of hematologic, other cancersJuly 20, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
EC approves new use, formulation of dasatinibJuly 6, 2018Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyCML
Cost of imatinib still high despite generic options, team saysMay 8, 2018Leukemia, Myelodysplasia, TransplantationPharmacyCML
CHMP backs approval of dasatinib for kidsApril 30, 2018Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyCML
